A Phase II Clinical Trial Of Thalidomide, Adramycin And Dexamethasone (TAD) As Initial Therapy For The Treatment Of Multiple Myeloma
OBJECTIVES: I. Determine the response rate of patients with previously untreated stage II or
III multiple myeloma treated with thalidomide, doxorubicin, and dexamethasone. II. Determine
the safety and toxicity of this regimen in this patient population.
OUTLINE: Patients receive oral dexamethasone on days 1-4, 9-12, and 17-20, doxorubicin IV on
day 1, and oral thalidomide daily. Treatment repeats every 30 days for 4 courses in the
absence of unacceptable toxicity or disease progression.
PROJECTED ACCRUAL: A total of 21-45 patients will be accrued for this study within
approximately 1 year.
Primary Purpose: Treatment
Raymond L. Comenzo, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|